AKROUnknownMid-Cap
Akero Therapeutics, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Akero Therapeutics, Inc. (AKRO), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud Research Team · SEC Form 4 & insider trading data analysts
Last updated:
Quick Answer
Are AKRO insiders buying or selling?
Akero Therapeutics, Inc. insiders reported 17 open-market buys ($138.1M) and 231 sells ($249.9M) across 248 Form 4 filings — a net selling position of $111.8M.
Source: SEC EDGAR Form 4
Key Statistics (as of Oct 15, 2025)
Total Form 4 filings
248
SEC EDGAR
Insider filers
18
Insider buys (17)
$138.1M
Insider sells (231)
$249.9M
Insider sentiment
Net sellingNet insider flow of $111.8M in net selling.
Recent AKRO insider transactions
| Date | Insider | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Oct 15, 2025 | Andrew Cheng | President and CEO | Sale | 30.0K | $53.98 | $1.6M |
| Oct 9, 2025 | Timothy Rolph | Chief Scientific Officer | Sale | 12.5K | $46.08 | $576.0K |
| Oct 3, 2025 | Jonathan Young | Chief Operating Officer | Sale | 12.5K | $47.76 | $597.0K |
| Sep 13, 2025 | Jonathan Young | Chief Operating Officer | Sale | 586 | $43.02 | $25.2K |
| Sep 13, 2025 | Catriona Yale | Chief Development Officer | Sale | 659 | $43.02 | $28.4K |
| Sep 13, 2025 | William Richard White | Chief Financial Officer | Sale | 659 | $43.02 | $28.4K |
| Sep 13, 2025 | Timothy Rolph | Chief Scientific Officer | Sale | 553 | $43.02 | $23.8K |
| Sep 13, 2025 | Andrew Cheng | President and CEO | Sale | 31.8K | $43.23 | $1.4M |
| Sep 10, 2025 | Timothy Rolph | Chief Scientific Officer | Sale | 12.5K | $44.17 | $552.1K |
| Sep 4, 2025 | Jonathan Young | Chief Operating Officer | Sale | 12.5K | $46.08 | $576.0K |
| Aug 13, 2025 | Jonathan Young | Chief Operating Officer | Sale | 12.5K | $47.79 | $597.3K |
| Aug 13, 2025 | Andrew Cheng | President and CEO | Sale | 30.0K | $48.59 | $1.5M |
| Aug 13, 2025 | Jane Henderson | Director | Sale | 3.0K | $47.46 | $142.4K |
| Aug 7, 2025 | Timothy Rolph | Chief Scientific Officer | Sale | 12.5K | $49.30 | $616.3K |
| Jul 18, 2025 | Catriona Yale | Chief Development Officer | Sale | 10.0K | $52.95 | $529.5K |
| Jul 11, 2025 | Andrew Cheng | President and CEO | Sale | 30.0K | $51.16 | $1.5M |
| Jul 9, 2025 | Timothy Rolph | Chief Scientific Officer | Sale | 12.5K | $51.09 | $638.7K |
| Jul 3, 2025 | Patrick Lamy | Senior VP, Commercial Strategy | Sale | 2.0K | $52.88 | $105.8K |
| Jun 21, 2025 | Andrew Cheng | President and CEO | Sale | 6.6K | $54.84 | $363.0K |
| Jun 21, 2025 | Scott A. Gangloff | Chief Technology Officer | Sale | 848 | $54.84 | $46.5K |
| Jun 21, 2025 | Patrick Lamy | Senior VP, Commercial Strategy | Sale | 875 | $54.59 | $47.8K |
| Jun 21, 2025 | Timothy Rolph | Chief Scientific Officer | Sale | 1.1K | $54.84 | $61.9K |
| Jun 21, 2025 | William Richard White | Chief Financial Officer | Sale | 1.6K | $54.84 | $89.6K |
| Jun 21, 2025 | Catriona Yale | Chief Development Officer | Sale | 1.6K | $54.84 | $89.6K |
| Jun 21, 2025 | Jonathan Young | Chief Operating Officer | Sale | 1.5K | $54.84 | $79.7K |
Showing the 25 most recent of 248 Form 4 filings for Akero Therapeutics, Inc..
Most active AKRO insiders
- Andrew Cheng46 filings
- Jonathan Young42 filings
- Catriona Yale40 filings
- Timothy Rolph31 filings
- William Richard White28 filings
Ask anything about AKRO insider activity
Use Trabud's AI agent to query Akero Therapeutics, Inc.'s Form 4 history in plain English — "Show me AKRO CEO purchases this year" or compare it against any other ticker.
Open the AI agentAKRO insider trading FAQ
Are Akero Therapeutics, Inc. insiders buying or selling?
Across 248 SEC Form 4 filings, Akero Therapeutics, Inc. (AKRO) insiders reported 17 open-market purchases totaling $138.1M and 231 sales totaling $249.9M. That is a net selling position of $111.8M.
How many insiders trade AKRO stock?
18 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Akero Therapeutics, Inc.. The most recent filing was accepted on Oct 15, 2025.
Where does Trabud get AKRO insider trading data?
All AKRO insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.
Looking for another company? Browse all tracked companies.